The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability
Background: The microvascular contrast agent transfer constant K trans has shown prognostic value in cervical cancer patients treated with chemoradiotherapy. This study aims to determine whether this is explained by the contribution to K trans of plasma flow ( F p ), vessel permeability surface-area...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2017-05, Vol.116 (11), p.1436-1443 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
The microvascular contrast agent transfer constant
K
trans
has shown prognostic value in cervical cancer patients treated with chemoradiotherapy. This study aims to determine whether this is explained by the contribution to
K
trans
of plasma flow (
F
p
), vessel permeability surface-area product (
PS
), or a combination of both.
Methods:
Pre-treatment dynamic contrast-enhanced MRI (DCE-MRI) data from 36 patients were analysed using the two-compartment exchange model. Estimates of
F
p
, PS, K
trans
, and fractional plasma and interstitial volumes (
v
p
and
v
e
) were made and used in univariate and multivariate survival analyses adjusting for clinicopathologic variables tumour stage, nodal status, histological subtype, patient age, tumour volume, and treatment type (chemoradiotherapy
vs
radiotherapy alone).
Results:
In univariate analyses,
F
p
(HR=0.25,
P
=0.0095) and
K
trans
(HR=0.20,
P
=0.032) were significantly associated with disease-free survival while
PS
,
v
p
and
v
e
were not. In multivariate analyses adjusting for clinicopathologic variables,
F
p
and
K
trans
significantly increased the accuracy of survival predictions (
P
=0.0089).
Conclusions:
The prognostic value of
K
trans
in cervical cancer patients treated with chemoradiotherapy is explained by microvascular plasma flow (
F
p
) rather than vessel permeability surface-area product (
PS
). |
---|---|
ISSN: | 0007-0920 1532-1827 1532-1827 |
DOI: | 10.1038/bjc.2017.121 |